A method for treating cancer using HDAC10 inhibitors
Cancer remains the second leading cause of death in the United States. Lung cancer is is responsible for the most cancer deaths, while prostate and ovary cancers are also in the top ten. HDAC inhibitors are promising anti-tumor agents that can effectively induce cancer cell death and growth arrest, but these have yet to be approved for treating these significant contributors to cancer deaths. There remains a need for improved methods of treating cancer.
Duke inventors have reported a method to treat lung, cervical, prostate and ovarian cancer. This technology can also be used to identify HDAC10 inhibitors. Specifically, the researchers have found that a combination treatment including an HDAC10 inhibitor can cause growth arrest and cell death in cancer cells for prostate, ovary, and lung. This has been demonstrated in numerous cellular studies.
- A promising strategy for treating lung, cervical, prostate and ovarian cancers
- Offers a method for screening new drug compounds
- Demonstrated with cell studies